X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23) 23
index medicus (19) 19
diabetes (18) 18
diabetes mellitus, type 2 - drug therapy (18) 18
male (18) 18
middle aged (17) 17
female (16) 16
aged (15) 15
type 2 diabetes (14) 14
hypoglycemic agents - therapeutic use (13) 13
metformin (13) 13
diabetes mellitus, type 2 - blood (12) 12
insulin (12) 12
abridged index medicus (10) 10
diabetes mellitus (10) 10
endocrinology & metabolism (10) 10
medicine, general & internal (10) 10
double-blind method (9) 9
drug therapy (9) 9
metformin - therapeutic use (9) 9
adult (8) 8
cardiovascular disease (8) 8
clinical trials (8) 8
diabetes mellitus, type 2 - complications (7) 7
hypoglycemic agents - adverse effects (7) 7
analysis (6) 6
care and treatment (6) 6
dosage and administration (6) 6
risk (6) 6
aged, 80 and over (5) 5
body mass index (5) 5
cerebral infarction (5) 5
drug therapy, combination (5) 5
follow-up studies (5) 5
hypoglycemic agents - administration & dosage (5) 5
insulin - therapeutic use (5) 5
myocardial infarction (5) 5
treatment outcome (5) 5
type 2 diabetes mellitus (5) 5
cardiovascular diseases (4) 4
diagnosis (4) 4
drug administration schedule (4) 4
glycated hemoglobin a - analysis (4) 4
glycated hemoglobin a - metabolism (4) 4
heart diseases (4) 4
mellitus (4) 4
metabolism (4) 4
mortality (4) 4
pancreatitis (4) 4
patient outcomes (4) 4
patients (4) 4
research (4) 4
risk factors (4) 4
blood glucose - drug effects (3) 3
blood glucose - metabolism (3) 3
blood pressure - drug effects (3) 3
c-reactive protein (3) 3
cardiovascular diseases - mortality (3) 3
cardiovascular diseases - prevention & control (3) 3
complication (3) 3
complications (3) 3
diabetes mellitus, type 2 - genetics (3) 3
diabetes mellitus, type 2 - physiopathology (3) 3
disease (3) 3
glycemic control (3) 3
health risk assessment (3) 3
hematology (3) 3
homocysteine (3) 3
insulin - administration & dosage (3) 3
kaplan-meier estimate (3) 3
management (3) 3
medical research (3) 3
metaanalysis (3) 3
metformin - administration & dosage (3) 3
obesity (3) 3
overweight - complications (3) 3
pancreatic cancer (3) 3
peptides (3) 3
pharmacokinetics (3) 3
prospective studies (3) 3
side effects (3) 3
therapy (3) 3
trial (3) 3
usage (3) 3
vitamin deficiency (3) 3
age factors (2) 2
animals (2) 2
association (2) 2
b12 (2) 2
beta cell function (2) 2
biomarkers - blood (2) 2
blood pressure (2) 2
blood-glucose control (2) 2
cardiovascular diseases - complications (2) 2
cardiovascular-disease (2) 2
clinical medicine (2) 2
clinical-chemistry (2) 2
cobalamin (2) 2
confidence intervals (2) 2
dapagliflozin (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Medical Journal, ISSN 0959-8146, 11/2009, Volume 339, Issue 7730, p. 1093
Metformin is the cornerstone of treatment early in the course of type 2 diabetes. Recent studies also provide evidence for the benefits of metformin when given... 
Obesity | Clinical trials | Diabetes | Drug therapy | Insulin
Journal Article
by Hernandez, Adrian F and Green, Fiona and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Michael and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Rosenberg, Anne and Sigmon, Kristina and Sigmon, Kristina N and Somerville, Matthew and Somerville, Matthew C and Thorpe, Karl and Thorpe, Karl M and McMurray, John J V and McMurray, John J.V and Del Prato, Stefano and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Patel, Rajesh and Patel, Vickas and Patel, Prashant and Patel, Rajivkumar and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Harrison, Lindsay and Lopes, Renato and Mathews, Robin and Mehta, Anand and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Deb and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, John and Cooper, Lauren and Sharma, Abhinav and Sharma, Richa and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Wilson, Tim and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and James, Rachel and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Johnson, David and Johnson, Andrew and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Judith and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and ... and Harmony Outcomes Comm Investigator and Harmony Outcomes committees and investigators
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment
Journal Article
Nature Genetics, ISSN 1061-4036, 09/2016, Volume 48, Issue 9, pp. 1055 - 1059
Journal Article
Diabetes obesity & metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1951 - 1956
Aims To study the effects of metformin, as compared to placebo, on serum levels of vitamin D (25-hydroxyvitamin D [25(OH)D]) in patients with advanced type 2... 
complication | CLINICAL-TRIAL | vitamin D | D SUPPLEMENTATION | D DEFICIENCY | MACROVASCULAR DISEASE | ADULTS | metformin | RISK | MELLITUS | INSULIN SENSITIVITY | METABOLISM | type 2 diabetes mellitus | GLUCOSE-TOLERANCE | ENDOCRINOLOGY & METABOLISM | Overweight - complications | Metformin - therapeutic use | Prevalence | Age Factors | Follow-Up Studies | Vitamin D Deficiency - complications | Humans | Middle Aged | Netherlands - epidemiology | Vitamin D Deficiency - chemically induced | Male | Metformin - adverse effects | Female | Seasons | Diabetes Mellitus, Type 2 - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Calcifediol - blood | Double-Blind Method | Diabetes Mellitus, Type 2 - blood | Vitamin D Deficiency - epidemiology | Nutritional Status - drug effects | Sex Factors | 25-Hydroxyvitamin D 2 - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Outpatient Clinics, Hospital | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Diet therapy | Vitamin D | Analysis | Clinical trials | Calcifediol | Hypoglycemic agents | Alfacalcidol | Diabetes therapy | Nutrient deficiency | Diabetes mellitus | Vitamin deficiency | Vitamin B12 | Insulin | Patients | Serum levels | Seasonal variations | Diabetes | Metformin | Diabetes mellitus (non-insulin dependent) | 25-Hydroxyvitamin D
Journal Article
JOURNAL OF DIABETES AND ITS COMPLICATIONS, ISSN 1056-8727, 02/2018, Volume 32, Issue 2, pp. 171 - 178
Aims: Metformin treatment is associated with a decrease of serum vitamin B12, but whether this reflects tissue B12 deficiency is controversial. We studied the... 
HOMOCYSTEINE | DIAGNOSIS | POLYNEUROPATHY | B12 | VITAMIN-B-12 DEFICIENCY | Type 2 diabetes mellitus | Neuropathy | COBALAMIN | MELLITUS | Methylmalonic acid | DISEASE | Complication | PERIPHERAL NEUROPATHY | Metformin | OUTCOMES | ASSOCIATION | VITAMIN-B12 DEFICIENCY | ENDOCRINOLOGY & METABOLISM
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 219 - 223
Metformin prevents weight gain in patients with type 2 diabetes (T2D). However, the mechanisms involved are still unknown. In this post hoc analysis of the... 
weight gain | Science | Healthy Ageing | Healthy ageing at work | gewichtstoename | diabetes | Nutrition and Dietetics | randomised | type 2 diabetes | metformin | appetite control | insulin therapy | obesity therapy | trial | OBESITY | THERAPY | FOOD-INTAKE | ENDOCRINOLOGY & METABOLISM | Overweight - complications | Metformin - therapeutic use | Follow-Up Studies | Overweight - drug therapy | Humans | Middle Aged | Male | Appetite Depressants - therapeutic use | Anti-Obesity Agents - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Aged, 80 and over | Adult | Female | Weight Gain - drug effects | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Obesity - chemically induced | Double-Blind Method | Obesity - complications | Obesity - physiopathology | Energy Intake - drug effects | Diabetes Mellitus, Type 2 - blood | Overweight - etiology | Obesity - prevention & control | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Type 2 diabetes | Prevention | Obesity | Diabetics | Care and treatment | Analysis | Body weight | Clinical trials | Metformin | Insulin | Energy intake | Dietary intake | Diabetes mellitus
Journal Article
Diabetes obesity & metabolism, ISSN 1462-8902, 03/2018, Volume 20, Issue 3, pp. 730 - 733
In this trial, 390 insulin-treated patients with type 2 diabetes were randomized to either placebo or metformin. Fasting levels of glucose, insulin and C... 
RCT | type 2 diabetes | PANCREATIC-ISLETS | SENSITIVITY | metformin | C-PEPTIDE | SECRETION | HOME study | beta cell function | GLUCOSE-TOLERANCE | BETA | ENDOCRINOLOGY & METABOLISM | Type 2 diabetes | Pancreatic beta cells | Care and treatment | Peptides | Analysis | Clinical trials | Metformin | Insulin | Diabetes therapy
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1951 - 1956
Journal Article
Journal of Diabetes and Its Complications, ISSN 1056-8727, 02/2018, Volume 32, Issue 2, pp. 171 - 178
Metformin treatment is associated with a decrease of serum vitamin B12, but whether this reflects tissue B12 deficiency is controversial. We studied the... 
Complication | B12 | Type 2 diabetes mellitus | Metformin | Neuropathy | Methylmalonic acid
Journal Article
Clinical Pharmacology and Therapeutics, ISSN 0009-9236, 06/2017, Volume 101, Issue 6, pp. 763 - 772
textabstractTherapeutic response to metformin, a first-line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic factors. To date,... 
JAK INHIBITOR | ACTIVE RHEUMATOID-ARTHRITIS | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | DISEASE PROGRESSION MODEL | DOSING FREQUENCY | INHIBITOR TOFACITINIB CP-690,550 | METHOTREXATE |